4/16
01:31 pm
podd
Abbott US diabetes device sales up 27% amid largely positive Q1 [Yahoo! Finance]
Low
Report
Abbott US diabetes device sales up 27% amid largely positive Q1 [Yahoo! Finance]
4/11
06:34 am
podd
The Week in Canadian Press Releases: 10 Stories You Need to See [Globe and Mail, The (Toronto, Canada)]
Low
Report
The Week in Canadian Press Releases: 10 Stories You Need to See [Globe and Mail, The (Toronto, Canada)]
4/7
01:45 pm
podd
This Insulin Pump Maker Expands Into New Territory And Its Stock Shows Relative Strength [Yahoo! Finance]
Low
Report
This Insulin Pump Maker Expands Into New Territory And Its Stock Shows Relative Strength [Yahoo! Finance]
4/3
06:00 am
podd
Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025
Low
Report
Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025
3/27
07:53 am
podd
3 Reasons Investors Love Insulet (PODD) [Yahoo! Finance]
Low
Report
3 Reasons Investors Love Insulet (PODD) [Yahoo! Finance]
3/21
06:46 am
podd
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers [Yahoo! Finance]
Low
Report
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers [Yahoo! Finance]
3/19
04:08 pm
podd
Insulet's RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections [Yahoo! Finance]
Low
Report
Insulet's RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections [Yahoo! Finance]
3/19
04:01 pm
podd
Insulet’s RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections
Low
Report
Insulet’s RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections
3/18
04:32 pm
podd
Insulet Announces Pricing of Senior Notes Due 2033
Low
Report
Insulet Announces Pricing of Senior Notes Due 2033
3/18
07:35 am
podd
Insulet Announces Proposed Financing Transactions
Low
Report
Insulet Announces Proposed Financing Transactions
3/18
06:29 am
podd
From Injections to Innovation – Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod® 5 in Adults and Children with Type 1 Diabetes [Yahoo! Finance]
Low
Report
From Injections to Innovation – Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod® 5 in Adults and Children with Type 1 Diabetes [Yahoo! Finance]
3/18
06:05 am
podd
Insulet Expands Omnipod® 5 to Four More International Markets
Low
Report
Insulet Expands Omnipod® 5 to Four More International Markets
3/18
06:00 am
podd
From Injections to Innovation – Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod® 5 in Adults and Children with Type 1 Diabetes
Low
Report
From Injections to Innovation – Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod® 5 in Adults and Children with Type 1 Diabetes
3/11
06:37 am
podd
Insulet to Host Investor Day on June 5, 2025 [Yahoo! Finance]
Medium
Report
Insulet to Host Investor Day on June 5, 2025 [Yahoo! Finance]
3/11
06:00 am
podd
Insulet to Host Investor Day on June 5, 2025
Medium
Report
Insulet to Host Investor Day on June 5, 2025
3/6
07:49 am
podd
Insulet Co. (NASDAQ: PODD) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $340.00 price target on the stock.
Medium
Report
Insulet Co. (NASDAQ: PODD) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $340.00 price target on the stock.
3/4
02:09 am
podd
Insulet Co. (NASDAQ: PODD) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Insulet Co. (NASDAQ: PODD) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
2/26
01:16 pm
podd
Insulet Sales Keep Rising [Yahoo! Finance]
Low
Report
Insulet Sales Keep Rising [Yahoo! Finance]
2/24
11:02 pm
podd
Insulet Co. (NASDAQ: PODD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Medium
Report
Insulet Co. (NASDAQ: PODD) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
2/24
08:41 am
podd
Earnings To Watch: Masimo (MASI) Reports Q4 Results Tomorrow [Yahoo! Finance]
Low
Report
Earnings To Watch: Masimo (MASI) Reports Q4 Results Tomorrow [Yahoo! Finance]
2/21
07:07 pm
podd
PODD Stock Falls Despite Q4 Earnings and Revenue Beat, Margins Rise [Yahoo! Finance]
Low
Report
PODD Stock Falls Despite Q4 Earnings and Revenue Beat, Margins Rise [Yahoo! Finance]
2/21
01:15 pm
podd
Insulet Co. (NASDAQ: PODD) had its price target raised by analysts at Citigroup Inc. from $310.00 to $355.00. They now have a "buy" rating on the stock.
Low
Report
Insulet Co. (NASDAQ: PODD) had its price target raised by analysts at Citigroup Inc. from $310.00 to $355.00. They now have a "buy" rating on the stock.
2/21
11:10 am
podd
Insulet Co. (NASDAQ: PODD) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $328.00 price target on the stock, up previously from $294.00.
Low
Report
Insulet Co. (NASDAQ: PODD) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $328.00 price target on the stock, up previously from $294.00.
2/21
09:53 am
podd
Insulet Co. (NASDAQ: PODD) had its price target raised by analysts at Stifel Nicolaus from $245.00 to $293.00. They now have a "hold" rating on the stock.
Low
Report
Insulet Co. (NASDAQ: PODD) had its price target raised by analysts at Stifel Nicolaus from $245.00 to $293.00. They now have a "hold" rating on the stock.
2/21
09:32 am
podd
Insulet Co. (NASDAQ: PODD) had its price target raised by analysts at Piper Sandler from $285.00 to $310.00. They now have an "overweight" rating on the stock.
Low
Report
Insulet Co. (NASDAQ: PODD) had its price target raised by analysts at Piper Sandler from $285.00 to $310.00. They now have an "overweight" rating on the stock.